AbbVie Inc. $ABBV Stock Position Lessened by Lynch & Associates IN

Lynch & Associates IN trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 70,546 shares of the company’s stock after selling 2,815 shares during the period. AbbVie makes up 3.2% of Lynch & Associates IN’s investment portfolio, making the stock its 7th largest holding. Lynch & Associates IN’s holdings in AbbVie were worth $16,334,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie during the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie in the 2nd quarter worth $26,000. TD Capital Management LLC grew its holdings in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares during the period. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie in the second quarter worth $28,000. Finally, Financial Gravity Companies Inc. purchased a new stake in AbbVie during the second quarter valued at $36,000. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ABBV. Piper Sandler reissued an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. UBS Group raised their price objective on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their target price for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Finally, BMO Capital Markets boosted their price objective on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research report on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $224.32 on Thursday. The company has a market capitalization of $396.47 billion, a P/E ratio of 169.94, a P/E/G ratio of 1.27 and a beta of 0.36. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The firm’s 50 day simple moving average is $226.87 and its two-hundred day simple moving average is $210.61. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 496.97%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.